World Hepatitis Day

World Hepatitis Day

Taking place on the 28th July every year, World Hepatitis Day strives to raise awareness of viral hepatitis one of the leading causes of death globally.1 An estimated 325 million people were living with chronic hepatitis infections (HBV or HCV) worldwide in 2015 and this global epidemic accounted for 1.34 million deaths that same year.1 Currently, 90% of people living with hepatitis B and 80% living with hepatitis C are not aware of their status.2

Key Facts

  • Hepatitis is an inflammation of the liver
  • There are 5 main hepatitis viruses, types A, B, C, D and E. Types B and C lead to chronic disease
  • Hepatitis A and E are typically caused by ingestion of contaminated food or water
  • Hepatitis B, C and D usually occur as a result of parenteral contact with infected body fluids
  • Acute infection may occur with limited or no symptoms, they may include; jaundice, dark urine, extreme fatigue, nausea, vomiting and abdominal pain3

At the 69th World Health Assembly in Geneva, 194 governments adopted the World Health Organisation’s Global Strategy on Viral Hepatitis, which includes a goal of eliminating viral hepatitis as a public health threat by 2030.

BBI Solutions’ R&D teams have a wealth of experience in developing highly responsive point-of-care lateral flow assays for the detection of infectious diseases. Whether you are looking to develop a new point-of-care assay or improve an existing diagnostic test, we offer end-to-end services to deliver robust and reproducible tests ready for the global market. If you have a question about developing a rapid diagnostic assay or about developing a lateral flow device, get in touch with our team today or drop by booth #1539 at AACC 1st-3rd August in San Diego.

Alternatively, BBI also offer a wide range of reagents used for the in-vitro diagnostics market, for the discovery, treatment and hopefully the subsequent elimination of viral hepatitis. See below for our range of products.

Antibody recommended matched pairs

  • HBsAg Total monoclonal antibody: BM310-P5H3 recommended as a detection antibody paired with BM310-V8G2 as a capture antibody
  • HBsAg Total monoclonal antibody: BM310-Z2E8 recommended as a detection (conjugated) antibody paired with BM310-V4F9 as a capture antibody
  • CEA Monoclonal Antibody: BM220-D7C6 recommended as a detection antibody paired with BM220-E1E3 as a capture antibody

Antigens

Disease State Plasma

Normal Serum

Conjugates

References

1. World Health Organisation: http://www.who.int/hepatitis/en/
2. World Hepatitis Day: http://www.worldhepatitisday.org/en/about-us
3. World Health Organisation: http://www.who.int/features/qa/76/en/



Copyright © 2017 BBI Solutions. All rights reserved. Designed trademarks and brands are the property of their respective owners. BBIUS